Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 88

1.

The Role of Calcitonin in Predicting the Extent of Surgery in Medullary Thyroid Carcinoma: A Nationwide Population-Based Study in Norway.

Opsahl EM, Akslen LA, Schlichting E, Aas T, Brauckhoff K, Hagen AI, Rosenlund AF, Sigstad E, Grøholt KK, Jørgensen LH, Bjøro T.

Eur Thyroid J. 2019 Jun;8(3):159-166. doi: 10.1159/000499018. Epub 2019 Apr 29.

2.

Drug monitoring of tamoxifen metabolites predicts vaginal dryness and verifies a low discontinuation rate from the Norwegian Prescription Database.

Helland T, Hagen KB, Haugstøyl ME, Kvaløy JT, Lunde S, Lode K, Lind RA, Gripsrud BH, Jonsdottir K, Gjerde J, Bifulco E, Hustad S, Jonassen J, Aas T, Lende TH, Lien EA, Janssen EAM, Søiland H, Mellgren G.

Breast Cancer Res Treat. 2019 Aug;177(1):185-195. doi: 10.1007/s10549-019-05294-w. Epub 2019 May 29.

PMID:
31144152
3.

Corrigendum to "Adherence to adjuvant endocrine therapy in postmenopausal breast cancer patients: A 5-year prospective study" [The Breast, 44, April 2019, 52-58].

Hagen KB, Aas T, Kvaløy JT, Søiland H, Lindb R.

Breast. 2019 Jun;45:118. doi: 10.1016/j.breast.2019.03.007. Epub 2019 Apr 5. No abstract available.

PMID:
30959387
4.

Trends in Diagnostics, Surgical Treatment, and Prognostic Factors for Outcomes in Medullary Thyroid Carcinoma in Norway: A Nationwide Population-Based Study.

Opsahl EM, Akslen LA, Schlichting E, Aas T, Brauckhoff K, Hagen AI, Rosenlund AF, Sigstad E, Grøholt KK, Mæhle L, Engebretsen LF, Jørgensen LH, Varhaug JE, Bjøro T.

Eur Thyroid J. 2019 Jan;8(1):31-40. doi: 10.1159/000493977. Epub 2018 Nov 8.

5.

Adherence to adjuvant endocrine therapy in postmenopausal breast cancer patients: A 5-year prospective study.

Hagen KB, Aas T, Kvaløy JT, Søiland H, Lind R.

Breast. 2019 Apr;44:52-58. doi: 10.1016/j.breast.2019.01.003. Epub 2019 Jan 8. Erratum in: Breast. 2019 Jun;45:118.

PMID:
30641300
6.

Four new Ophiostoma species associated with hardwood-infesting bark beetles in Norway and Poland.

Aas T, Solheim H, Jankowiak R, Bilański P, Hausner G.

Fungal Biol. 2018 Dec;122(12):1142-1158. doi: 10.1016/j.funbio.2018.08.001. Epub 2018 Aug 17.

PMID:
30449352
7.

Three new Leptographium spp. (Ophiostomatales) infecting hardwood trees in Norway and Poland.

Jankowiak R, Ostafińska A, Aas T, Solheim H, Bilański P, Linnakoski R, Hausner G.

Antonie Van Leeuwenhoek. 2018 Dec;111(12):2323-2347. doi: 10.1007/s10482-018-1123-8. Epub 2018 Jul 6.

8.

Diet in women with breast cancer compared to healthy controls - What is the difference?

Hagen KB, Aas T, Kvaløy JT, Søiland H, Lind R.

Eur J Oncol Nurs. 2018 Feb;32:20-24. doi: 10.1016/j.ejon.2017.11.003. Epub 2017 Nov 24.

PMID:
29353628
9.

Injury mechanisms and electromyographic changes after injury of the recurrent laryngeal nerve: Experiments in a porcine model.

Brauckhoff K, Svendsen ØS, Stangeland L, Biermann M, Aas T, Husby PJA.

Head Neck. 2018 Feb;40(2):274-282. doi: 10.1002/hed.24940. Epub 2017 Sep 30.

PMID:
28963808
10.

Two new Leptographium spp. reveal an emerging complex of hardwood-infecting species in the Ophiostomatales.

Jankowiak R, Strzałka B, Bilański P, Linnakoski R, Aas T, Solheim H, Groszek M, de Beer ZW.

Antonie Van Leeuwenhoek. 2017 Dec;110(12):1537-1553. doi: 10.1007/s10482-017-0905-8. Epub 2017 Jul 7.

PMID:
28687978
11.

Effect of Surgery Versus Observation: Skeletal 5-Year Outcomes in a Randomized Trial of Patients With Primary HPT (the SIPH Study).

Lundstam K, Heck A, Godang K, Mollerup C, Baranowski M, Pernow Y, Aas T, Hessman O, Rosén T, Nordenström J, Jansson S, Hellström M, Bollerslev J; SIPH Study Group.

J Bone Miner Res. 2017 Sep;32(9):1907-1914. doi: 10.1002/jbmr.3177. Epub 2017 Jul 7.

12.

Expression of Nestin associates with BRCA1 mutations, a basal-like phenotype and aggressive breast cancer.

Krüger K, Wik E, Knutsvik G, Nalwoga H, Klingen TA, Arnes JB, Chen Y, Mannelqvist M, Dimitrakopoulou K, Stefansson IM, Birkeland E, Aas T, Tobin NP, Jonassen I, Bergh J, Foulkes WD, Akslen LA.

Sci Rep. 2017 Apr 24;7(1):1089. doi: 10.1038/s41598-017-00862-w.

13.

Extra-nodal extension is a significant prognostic factor in lymph node positive breast cancer.

Aziz S, Wik E, Knutsvik G, Klingen TA, Chen Y, Davidsen B, Aas H, Aas T, Akslen LA.

PLoS One. 2017 Feb 15;12(2):e0171853. doi: 10.1371/journal.pone.0171853. eCollection 2017.

14.

Tumour cell invasion into blood vessels is significantly related to breast cancer subtypes and decreased survival.

Klingen TA, Chen Y, Stefansson IM, Knutsvik G, Collett K, Abrahamsen AL, Aase H, Aas H, Aas T, Wik E, Akslen LA.

J Clin Pathol. 2017 Apr;70(4):313-319. doi: 10.1136/jclinpath-2016-203861. Epub 2016 Sep 9.

PMID:
27612505
15.

Fatigue, anxiety and depression overrule the role of oncological treatment in predicting self-reported health complaints in women with breast cancer compared to healthy controls.

Hagen KB, Aas T, Kvaløy JT, Eriksen HR, Søiland H, Lind R.

Breast. 2016 Aug;28:100-6. doi: 10.1016/j.breast.2016.05.005. Epub 2016 Jun 2.

PMID:
27262826
16.

EMG changes during continuous intraoperative neuromonitoring with sustained recurrent laryngeal nerve traction in a porcine model.

Brauckhoff K, Aas T, Biermann M, Husby P.

Langenbecks Arch Surg. 2017 Jun;402(4):675-681. doi: 10.1007/s00423-016-1419-y. Epub 2016 Apr 16.

17.

Evaluation of Tumor Cell Proliferation by Ki-67 Expression and Mitotic Count in Lymph Node Metastases from Breast Cancer.

Aziz S, Wik E, Knutsvik G, Klingen TA, Chen Y, Davidsen B, Aas H, Aas T, Akslen LA.

PLoS One. 2016 Mar 8;11(3):e0150979. doi: 10.1371/journal.pone.0150979. eCollection 2016.

18.

Impact of EMG Changes in Continuous Vagal Nerve Monitoring in High-Risk Endocrine Neck Surgery.

Brauckhoff K, Vik R, Sandvik L, Heimdal JH, Aas T, Biermann M, Brauckhoff M.

World J Surg. 2016 Mar;40(3):672-80. doi: 10.1007/s00268-015-3368-y.

19.

BRCA1/2 testing in newly diagnosed breast and ovarian cancer patients without prior genetic counselling: the DNA-BONus study.

Høberg-Vetti H, Bjorvatn C, Fiane BE, Aas T, Woie K, Espelid H, Rusken T, Eikesdal HP, Listøl W, Haavind MT, Knappskog PM, Haukanes BI, Steen VM, Hoogerbrugge N.

Eur J Hum Genet. 2016 Jun;24(6):881-8. doi: 10.1038/ejhg.2015.196. Epub 2015 Sep 9.

20.

Women treated with breast conserving surgery do better than those with mastectomy independent of detection mode, prognostic and predictive tumor characteristics.

Hofvind S, Holen Å, Aas T, Roman M, Sebuødegård S, Akslen LA.

Eur J Surg Oncol. 2015 Oct;41(10):1417-22. doi: 10.1016/j.ejso.2015.07.002. Epub 2015 Jul 17.

PMID:
26253193
21.

Subclonal diversification of primary breast cancer revealed by multiregion sequencing.

Yates LR, Gerstung M, Knappskog S, Desmedt C, Gundem G, Van Loo P, Aas T, Alexandrov LB, Larsimont D, Davies H, Li Y, Ju YS, Ramakrishna M, Haugland HK, Lilleng PK, Nik-Zainal S, McLaren S, Butler A, Martin S, Glodzik D, Menzies A, Raine K, Hinton J, Jones D, Mudie LJ, Jiang B, Vincent D, Greene-Colozzi A, Adnet PY, Fatima A, Maetens M, Ignatiadis M, Stratton MR, Sotiriou C, Richardson AL, Lønning PE, Wedge DC, Campbell PJ.

Nat Med. 2015 Jul;21(7):751-9. doi: 10.1038/nm.3886. Epub 2015 Jun 22.

22.

Concomitant inactivation of the p53- and pRB- functional pathways predicts resistance to DNA damaging drugs in breast cancer in vivo.

Knappskog S, Berge EO, Chrisanthar R, Geisler S, Staalesen V, Leirvaag B, Yndestad S, de Faveri E, Karlsen BO, Wedge DC, Akslen LA, Lilleng PK, Løkkevik E, Lundgren S, Østenstad B, Risberg T, Mjaaland I, Aas T, Lønning PE.

Mol Oncol. 2015 Oct;9(8):1553-64. doi: 10.1016/j.molonc.2015.04.008. Epub 2015 May 8.

23.

Illness uncertainty in breast cancer patients: validation of the 5-item short form of the Mishel Uncertainty in Illness Scale.

Hagen KB, Aas T, Lode K, Gjerde J, Lien E, Kvaløy JT, Lash TL, Søiland H, Lind R.

Eur J Oncol Nurs. 2015 Apr;19(2):113-9. doi: 10.1016/j.ejon.2014.10.009. Epub 2014 Dec 20.

PMID:
25538036
24.

Latencies longer than 3.5 ms after vagus nerve stimulation does not exclude a nonrecurrent inferior laryngeal nerve.

Brauckhoff M, Naterstad H, Brauckhoff K, Biermann M, Aas T.

BMC Surg. 2014 Aug 28;14:61. doi: 10.1186/1471-2482-14-61.

25.

TP53 status predicts long-term survival in locally advanced breast cancer after primary chemotherapy.

Eikesdal HP, Knappskog S, Aas T, Lønning PE.

Acta Oncol. 2014 Oct;53(10):1347-55. doi: 10.3109/0284186X.2014.922215. Epub 2014 Jun 9.

26.

Serum concentrations of tamoxifen and its metabolites increase with age during steady-state treatment.

Lien EA, Søiland H, Lundgren S, Aas T, Steen VM, Mellgren G, Gjerde J.

Breast Cancer Res Treat. 2013 Sep;141(2):243-8. doi: 10.1007/s10549-013-2677-9. Epub 2013 Sep 1.

27.

Physiotherapy after stroke: to what extent is task-oriented practice a part of conventional treatment after hospital discharge?

Askim T, Indredavik B, Engen A, Roos K, Aas T, Mørkved S.

Physiother Theory Pract. 2013 Jul;29(5):343-50. doi: 10.3109/09593985.2012.734008. Epub 2012 Oct 25.

PMID:
23098358
28.

Microvessel proliferation by co-expression of endothelial nestin and Ki-67 is associated with a basal-like phenotype and aggressive features in breast cancer.

Krüger K, Stefansson IM, Collett K, Arnes JB, Aas T, Akslen LA.

Breast. 2013 Jun;22(3):282-8. doi: 10.1016/j.breast.2012.07.008. Epub 2012 Jul 26.

29.

Glomeruloid microvascular proliferation is associated with lack of response to chemotherapy in breast cancer.

Akslen LA, Straume O, Geisler S, Sørlie T, Chi JT, Aas T, Børresen-Dale AL, Lønning PE.

Br J Cancer. 2011 Jun 28;105(1):9-12. doi: 10.1038/bjc.2011.203. Epub 2011 Jun 14.

30.

Predictive and prognostic impact of TP53 mutations and MDM2 promoter genotype in primary breast cancer patients treated with epirubicin or paclitaxel.

Chrisanthar R, Knappskog S, Løkkevik E, Anker G, Ostenstad B, Lundgren S, Risberg T, Mjaaland I, Skjønsberg G, Aas T, Schlichting E, Fjösne HE, Nysted A, Lillehaug JR, Lønning PE.

PLoS One. 2011 Apr 27;6(4):e19249. doi: 10.1371/journal.pone.0019249.

31.

Effects of a community-based intensive motor training program combined with early supported discharge after treatment in a comprehensive stroke unit: a randomized, controlled trial.

Askim T, Mørkved S, Engen A, Roos K, Aas T, Indredavik B.

Stroke. 2010 Aug;41(8):1697-703. doi: 10.1161/STROKEAHA.110.584284. Epub 2010 Jun 17.

PMID:
20558830
32.

DNA methylation profiling in doxorubicin treated primary locally advanced breast tumours identifies novel genes associated with survival and treatment response.

Dejeux E, Rønneberg JA, Solvang H, Bukholm I, Geisler S, Aas T, Gut IG, Børresen-Dale AL, Lønning PE, Kristensen VN, Tost J.

Mol Cancer. 2010 Mar 25;9:68. doi: 10.1186/1476-4598-9-68.

33.

Breast cancer aromatase expression evaluated by the novel antibody 677: correlations to intra-tumor estrogen levels and hormone receptor status.

Geisler J, Suzuki T, Helle H, Miki Y, Nagasaki S, Duong NK, Ekse D, Aas T, Evans DB, Lønning PE, Sasano H.

J Steroid Biochem Mol Biol. 2010 Feb 28;118(4-5):237-41. doi: 10.1016/j.jsbmb.2009.10.010. Epub 2009 Oct 31.

PMID:
19883757
34.

Tissue estradiol is selectively elevated in receptor positive breast cancers while tumour estrone is reduced independent of receptor status.

Lønning PE, Helle H, Duong NK, Ekse D, Aas T, Geisler J.

J Steroid Biochem Mol Biol. 2009 Oct;117(1-3):31-41. doi: 10.1016/j.jsbmb.2009.06.005. Epub 2009 Jul 8.

PMID:
19591931
35.

Letrozole is superior to anastrozole in suppressing breast cancer tissue and plasma estrogen levels.

Geisler J, Helle H, Ekse D, Duong NK, Evans DB, Nordbø Y, Aas T, Lønning PE.

Clin Cancer Res. 2008 Oct 1;14(19):6330-5. doi: 10.1158/1078-0432.CCR-07-5221.

36.

[Information before screening].

Aas T, Markestad T.

Tidsskr Nor Laegeforen. 2007 Oct 18;127(20):2705. Norwegian. No abstract available.

PMID:
17972392
37.

Gene expression profiles do not consistently predict the clinical treatment response in locally advanced breast cancer.

Sørlie T, Perou CM, Fan C, Geisler S, Aas T, Nobel A, Anker G, Akslen LA, Botstein D, Børresen-Dale AL, Lønning PE.

Mol Cancer Ther. 2006 Nov;5(11):2914-8.

38.

Genital ulcers as initial manifestation of Epstein-Barr virus infection: two new cases and a review of the literature.

Halvorsen JA, Brevig T, Aas T, Skar AG, Slevolden EM, Moi H.

Acta Derm Venereol. 2006;86(5):439-42. Erratum in: Acta Derm Venereol. 2006;86(6):482.

39.

Purine-induced expression of urate oxidase and enzyme activity in Atlantic salmon (Salmo salar). Cloning of urate oxidase liver cDNA from three teleost species and the African lungfish Protopterus annectens.

Andersen Ø, Aas TS, Skugor S, Takle H, van Nes S, Grisdale-Helland B, Helland SJ, Terjesen BF.

FEBS J. 2006 Jul;273(13):2839-50. Epub 2006 Jun 5.

40.

Expression of enhancer of zeste homologue 2 is significantly associated with increased tumor cell proliferation and is a marker of aggressive breast cancer.

Collett K, Eide GE, Arnes J, Stefansson IM, Eide J, Braaten A, Aas T, Otte AP, Akslen LA.

Clin Cancer Res. 2006 Feb 15;12(4):1168-74.

41.

Prognostic and predictive value of changes in tumour cell proliferation in locally advanced breast cancer primarily treated with doxorubicin.

Aas T, Geisler S, Helle H, Børresen-Dale AL, Lønning PE, Akslen LA.

Oncol Rep. 2005 Mar;13(3):525-30.

PMID:
15706428
42.

TP53 gene mutations predict the response to neoadjuvant treatment with 5-fluorouracil and mitomycin in locally advanced breast cancer.

Geisler S, Børresen-Dale AL, Johnsen H, Aas T, Geisler J, Akslen LA, Anker G, Lønning PE.

Clin Cancer Res. 2003 Nov 15;9(15):5582-8.

43.

Predictive value of tumour cell proliferation in locally advanced breast cancer treated with neoadjuvant chemotherapy.

Aas T, Geisler S, Eide GE, Haugen DF, Varhaug JE, Bassøe AM, Thorsen T, Berntsen H, Børresen-Dale AL, Akslen LA, Lønning PE.

Eur J Cancer. 2003 Mar;39(4):438-46.

PMID:
12751373
44.

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications.

Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Lønning PE, Børresen-Dale AL.

Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74.

45.

Plasma insulin-like growth factor binding protein-3 proteolysis is increased in primary breast cancer.

Helle SI, Geisler S, Aas T, Paulsen T, Holly JM, Lønning PE.

Br J Cancer. 2001 Jul 6;85(1):74-7.

46.

Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer.

Geisler S, Lønning PE, Aas T, Johnsen H, Fluge O, Haugen DF, Lillehaug JR, Akslen LA, Børresen-Dale AL.

Cancer Res. 2001 Mar 15;61(6):2505-12.

47.

Proton magnetic resonance spectroscopy of brain biopsies from patients with intractable epilepsy.

Aasly J, Silfvenius H, Aas TC, Sonnewald U, Olivecrona M, Juul R, White LR.

Epilepsy Res. 1999 Jul;35(3):211-7.

PMID:
10413316
48.

Angiogenesis does not predict clinical response to doxorubicin monotherapy in patients with locally advanced breast cancer.

Paulsen T, Aas T, Børresen AL, Varhaug JE, Lønning PE, Akslen LA.

Int J Cancer. 1997 Feb 20;74(1):138-40. No abstract available.

49.

Absence of p21 expression is associated with abnormal p53 in human breast carcinomas.

Ellis PA, Lonning PE, Borresen-Dale A, Aas T, Geisler S, Akslen LA, Salter I, Smith IE, Dowsett M.

Br J Cancer. 1997;76(4):480-5.

50.

Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients.

Aas T, Børresen AL, Geisler S, Smith-Sørensen B, Johnsen H, Varhaug JE, Akslen LA, Lønning PE.

Nat Med. 1996 Jul;2(7):811-4.

PMID:
8673929

Supplemental Content

Support Center